SCHEMBL21062072

SCHEMBL21062072

Clc1cc(N2CC(c3ccccc3)C2)nc2c1SCC2

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4D Q08499 1/20 0.39
ALDH1A1 P00352 7/20 0.38
MAPT P10636 6/20 0.38
NPC1 O15118 4/20 0.38
RAB9A P51151 4/20 0.38
SMN1; SMN2 Q16637 4/20 0.38
POLB P06746 2/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
BLM P54132 2/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
HTT P42858 3/20 0.36
KDM4E B2RXH2 1/20 0.36
HPGD P15428 1/20 0.36
CYP1A2 P05177 2/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
PDE11A Q9HCR9 3/20 0.34
PDE2A O00408 2/20 0.33
PDE4A P27815 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30712011 1.00 PDE4D (0.39) PDE4DALDH1A1MAPTNPC1RAB9A
SCHEMBL30712007 0.88 PDE4D (0.41) PDE4DALDH1A1MAPTNPC1RAB9A
SCHEMBL21062018 0.88 PDE4D (0.41) PDE4DALDH1A1MAPTNPC1RAB9A
SCHEMBL21062069 0.76 PDE4D (0.65) PDE4DALDH1A1PDE10APDE1BMAPK1
SCHEMBL30712012 0.76 PDE4D (0.65) PDE4DALDH1A1PDE10APDE1BMAPK1
SCHEMBL21062063 0.73 PDE4D (0.38) PDE4DALDH1A1MAPTNPC1RAB9A
SCHEMBL30712014 0.73 PDE4D (0.38) PDE4DALDH1A1MAPTNPC1RAB9A
SCHEMBL21130412 0.73 PDE4D (0.44) PDE4DALDH1A1MEN1KMT2AMAPK1
SCHEMBL30712013 0.73 PDE4D (0.44) PDE4DALDH1A1MEN1KMT2AMAPK1
SCHEMBL21062014 0.66 SMN1; SMN2 (0.38) ALDH1A1MAPTNPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240400578-A1 SUBSTITUTED AZETIDINE DIHYDROTHIENOPYRIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS UNION therapeutics A/S (DK) 2024-12-05 US disclosed
US-11981681-B2 Substituted azetidine dihydrothienopyridines and their use as phosphodiesterase inhibitors UNION therapeutics A/S (DK) 2024-05-14 US disclosed
CN-111727191-B Substituted azetidine dihydro-thienopyridines and their use as phosphodiesterase inhibitors 联合疗法公司 2024-01-05 CN disclosed
US-20230087354-A1 SUBSTITUTED AZETIDINE DIHYDROTHIENOPYRIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS UNION therapeutics A/S (DK) 2023-03-23 US disclosed
EP-3724196-B9 SUBSTITUTED AZETIDINE DIHYDROTHIENOPYRIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS UNION THERAPEUTICS AS (DK) 2023-03-22 EP disclosed
EP-3724196-B1 SUBSTITUTED AZETIDINE DIHYDROTHIENOPYRIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS UNION THERAPEUTICS AS (DK) 2022-11-16 EP disclosed
EP-3724196-B1 SUBSTITUTED AZETIDINE DIHYDROTHIENOPYRIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS UNION THERAPEUTICS AS (DK) 2022-11-16 EP disclosed
US-11384096-B2 Substituted azetidine dihydrothienopyridines and their use as phosphodiesterase inhibitors UNION therapeutics A/S (DK) 2022-07-12 US disclosed
US-11384096-B2 Substituted azetidine dihydrothienopyridines and their use as phosphodiesterase inhibitors UNION therapeutics A/S (DK) 2022-07-12 US disclosed
US-20210079012-A1 SUBSTITUTED AZETIDINE DIHYDROTHIENOPYRIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS UNION therapeutics A/S (DK) 2021-03-18 US disclosed
US-20210079012-A1 SUBSTITUTED AZETIDINE DIHYDROTHIENOPYRIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS UNION therapeutics A/S (DK) 2021-03-18 US disclosed
EP-3724196-A1 SUBSTITUTED AZETIDINE DIHYDROTHIENOPYRIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS Leo Pharma A/S (DK) 2020-10-21 EP disclosed
CN-111727191-A Substituted azetidine dihydrothienopyridines and their use as phosphodiesterase inhibitors 利奥制药有限公司 2020-09-29 CN disclosed
WO-2019115776-A1 SUBSTITUTED AZETIDINE DIHYDROTHIENOPYRIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS LEO PHARMA A/S (DK) 2019-06-20 WO disclosed
WO-2019115776-A1 SUBSTITUTED AZETIDINE DIHYDROTHIENOPYRIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS LEO PHARMA A/S (DK) 2019-06-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11384096-B2 Substituted azetidine dihydrothienopyridines and their use as phosphodiesterase inhibitors PDE2A, PDE3A, PDE3B PDE4D 12/4885ALDH1A1 548/4885MAPT 4080/4885
US-11981681-B2 Substituted azetidine dihydrothienopyridines and their use as phosphodiesterase inhibitors PDE2A, PDE3A, PDE3B PDE4D 12/4885ALDH1A1 548/4885MAPT 4080/4885
US-20240400578-A1 SUBSTITUTED AZETIDINE DIHYDROTHIENOPYRIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS PDE2A, PDE3A, PDE3B PDE4D 12/4885ALDH1A1 548/4885MAPT 4080/4885
US-20210079012-A1 SUBSTITUTED AZETIDINE DIHYDROTHIENOPYRIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS PDE2A, PDE3A, PDE3B PDE4D 12/4885ALDH1A1 548/4885MAPT 4080/4885
US-20230087354-A1 SUBSTITUTED AZETIDINE DIHYDROTHIENOPYRIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS PDE2A, PDE3A, PDE3B PDE4D 12/4885ALDH1A1 548/4885MAPT 4080/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.